-
DON Liver Injury: Mitophagy and Nrf2 Suppression
2026-09-14
The reference study proposes that deoxynivalenol causes liver injury through a coupled mechanism involving excessive PINK1/Parkin-mediated mitophagy and suppression of the p62-Keap1-Nrf2 antioxidant pathway. Mouse and AML-12 cell experiments, including mitophagy inhibition, PINK1 silencing, and p62 overexpression, provide a framework for interpreting mitochondrial damage, oxidative stress, inflammation, apoptosis, and lipid-metabolism disruption.
-
T7 RNA Polymerase: Reliable RNA Workflows
2026-09-14
This scenario-driven guide explains how T7 RNA Polymerase, SKU K1083, can standardize upstream RNA synthesis when cell viability, proliferation, or cytotoxicity results are difficult to interpret. It covers template compatibility, practical controls, protocol planning, data attribution, and evidence-based product selection without overstating enzyme performance.
-
E-64 Workflows for Cysteine Protease Studies
2026-09-13
E-64 combines low-nanomolar potency with irreversible active-site labeling, making it useful for enzyme kinetics, cathepsin inhibition, and mechanistic cell-death studies. This guide translates that chemistry into practical workflows for lysosomal protease research, cancer research, and troubleshooting assay variability.
-
C8-HSL Activates PI3K/AKT/ERK in Lung Cancer
2026-09-12
The reference study identifies the bacterial quorum-sensing molecule C8-HSL as a potential regulator of lung cancer cell behavior, linking microbial signaling with tumor-cell proliferation, migration, and invasion. Its findings connect these phenotypes to PI3K/AKT/ERK activation and provide a framework for investigating quorum-sensing signals in infection biology and lung tumor research.
-
AICAR Workflows for AMPK Inflammation Research
2026-09-11
AICAR provides a tunable way to activate AMPK while connecting energy metabolism regulation with macrophage inflammation assays. This practical guide covers cell-based workflows, pathway validation, formulation, controls, and troubleshooting informed by obesity-related asthma research.
-
Cyclophilin A Reveals Cyclosporine’s Immune Target
2026-09-11
The reference study used genetic deletion and complementary mouse models to show that cyclophilin A is the principal intracellular mediator of cyclosporine-induced immunosuppression. Its findings sharpen interpretation of calcineurin-inhibitor assays by separating CypA-dependent drug action from the broader physiological functions of cyclophilins.
-
Anti-RPS6 Antibody Workflows for PDAC Research
2026-09-10
Use the Anti-RPS6 (7B10) Mouse Monoclonal Antibody to connect protein abundance with ribosome biogenesis, biosynthetic growth, and proliferation in pancreatic cancer models. The workflow combines Western blot, ICC/IF, and immunoprecipitation so researchers can distinguish total RPS6 changes from phosphorylation-specific signaling.
-
Epoxomicin and the Next Logic of Proteostasis
2026-09-10
Epoxomicin offers translational researchers a precise way to perturb proteasomal protein degradation and connect catalytic inhibition with ER stress, inflammation, neurodegeneration, and cellular fate. This thought-leadership guide integrates mechanistic evidence on UBR1 and UBR2 with practical assay design, product-selection logic, and responsible interpretation beyond conventional product-page claims.
-
Bafilomycin C1 in High-Content Cell Assays
2026-09-09
Bafilomycin C1 is a vacuolar H+-ATPases inhibitor that can convert lysosomal acidification into a measurable phenotypic perturbation. This article explains how to integrate that mechanism with high-content imaging, autophagy assay design, and iPSC-derived cardiomyocyte screening without confusing phenotype with mechanism.
-
Carbapenemase Spread in Enterobacter cloacae
2026-09-09
Chen et al. integrate carbapenemase gene localization, plasmid-transfer testing, antimicrobial susceptibility, mobile-element analysis, and strain genotyping across eight teaching hospitals in Guangdong. Their findings identify plasmid-associated blaNDM-1 as a major transmission concern and show why CREC surveillance must distinguish horizontal gene transfer from clonal dissemination.
-
Biotin-XX Tyramide Reagent Workflow Guide
2026-09-08
Biotin-XX Tyramide Reagent combines HRP-triggered signal amplification with membrane-impermeant surface labeling for sensitive IHC, ISH, and proximity-proteomics workflows. This guide translates the reagent’s chemistry and serotonin-specific interference findings into practical setup, optimization, and troubleshooting decisions.
-
HA-LNP PTEN mRNA for Transdermal Melanoma Therapy
2026-09-08
The reference study develops a hyaluronate-conjugated lipid nanoparticle that delivers PTEN mRNA through the skin and targets CD44-expressing melanoma cells. Its findings connect localized tumor suppressor restoration with immunogenic cell death, immune activation, and tumor growth suppression, while highlighting formulation and translational questions for mRNA-based cancer research.
-
TPPU: A Causal Framework for sEH Assays
2026-09-07
TPPU is a potent soluble epoxide hydrolase inhibitor for dissecting fatty acid epoxide signaling, inflammation, and osteoclast biology. This article presents a tiered assay strategy that separates target engagement from lipid mediator changes, Nrf2 signaling, and disease-relevant phenotypes.
-
HyperPFU™ high-fidelity DNA polymerase Guide
2026-09-07
HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, or otherwise difficult DNA templates when blunt-ended products are acceptable. It should not be selected as the default enzyme for workflows requiring 3′-A overhangs, pre-formed sticky ends, or an unvalidated universal PCR recipe.
-
Sisomicin Activity Against Clinical Bacterial Isolates
2026-09-05
Stewart and Bodey evaluated sisomicin against 565 clinical isolates and found broad in vitro activity against gram-negative bacilli and gram-positive cocci, with performance generally comparable to or better than established aminoglycosides. The study is valuable as an early comparative susceptibility benchmark, while its historical isolate set and MIC-only design limit direct translation to current clinical treatment decisions.